https://doi.org/10.4081/reumatismo.2025.1693
Development of thymoma without myasthenia gravis in a patient with radiographic axial spondyloarthritis treated with tumor necrosis factor-α inhibitors
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 5 June 2025
Thymic tumors are rare in the general population, and to the best of our knowledge, no cases of thymoma have been described in patients with rheumatic diseases treated with tumor necrosis factor (TNF)-α inhibitors, except for the case of a patient receiving infliximab for Crohn’s disease (CD) who developed a B2 thymoma. We describe a 60-year-old Caucasian male with radiographic axial spondyloarthritis (r-axSpA) and CD who developed an AB-type thymoma without myasthenia gravis after 18 years of treatment with TNF-α inhibitors. The patient had received the same molecule since the r-axSpA/CD diagnosis and changed it 6 months before the diagnosis of thymoma due to a disease flare. At the time of the drug switch, no mediastinal mass was present on the chest X-ray. The thymoma was surgically removed, and no additional therapy was needed. Treatment with TNF-α inhibitors was reintroduced after surgery. This case raises some important questions that remain open and deserve to be addressed in the future, such as the association between immunosuppressive therapy and thymoma and the controversial relationship between TNF-α inhibitors and myasthenia gravis.
Downloads
Marx A, Chan JKC, Chalabreysse L, Dacic S, Detterbeck F, French CA, et al. The 2021 WHO classification of tumors of the thymus and mediastinum: what is new in thymic epithelial, germ cell, and mesenchymal tumors? J Thorac Oncol 2022; 17: 200-13. DOI: https://doi.org/10.1016/j.jtho.2021.10.010
Huss V, Bower H, Hellgren K, Frisell T, Asklling J. Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study. Ann Rheum Dis 2023; 82: 911-9. DOI: https://doi.org/10.1136/ard-2022-223636
Seror R, Lafourcade A, De Rycke Y, Pinto S, Castaneda J, Fautrel B, et al. Risk of malignancy in rheumatoid arthritis patients initiating biologics: an historical propensity score matched cohort study within the French nationwide healthcare database. RMD Open 2022; 8: e002139. DOI: https://doi.org/10.1136/rmdopen-2021-002139
Konso M, El Bacha H, Dilal S, Mendes P, Znati K, Benzzoubeir N, et al. Development of thymoma during anti-TNF alpha therapy: coincidence or consequence. IAR J Med Cse Rep 2023; 4: 19-21.
Rich AL. Epidemiology of thymoma. J Thorac Dis 2020; 12: 7531-5. DOI: https://doi.org/10.21037/jtd-2019-thym-02
Blum TG, Misch D, Kollmeier J, Thiel S, Bauer TT. Autoimmune disorders and paraneoplastic syndromes in thymoma. J Thorac Dis 2020; 12: 7571-90. DOI: https://doi.org/10.21037/jtd-2019-thym-10
Souadjian JV, Enriquez P, Silverstein MN, Pepin JM. The spectrum of diseases associated with thymoma. Arch Intern Med 1974; 134: 374-9. DOI: https://doi.org/10.1001/archinte.1974.00320200184029
Teramatsu T, Yamamoto H, Matsutani Y. Mediastinal tumors in Japan survey. Jpn J Thorac Surg 1976; 24: 270-3.
Okubo K, Kondo N, Okamoto T, Isobe J, Ueno Y. Excision of an invasive thymoma: a cure for ulcerative colitis? Case Reports Ann Thorac Surg 2001; 71: 2013-5. DOI: https://doi.org/10.1016/S0003-4975(00)02501-7
De Rosa A, Fornili M, Maestri Tassoni M, Guida M, Baglietto L, Petrucci L, et al. Thymoma-associated myasthenia gravis: Clinical features and predictive value of antiacetylcholine receptor antibodies in the risk of recurrence of thymoma. Thorac Cancer 2021; 12: 106-13. DOI: https://doi.org/10.1111/1759-7714.13724
Berrih-Aknin S, Le Panse R. Myasthenia gravis: a comprehensive review of immune dysregulation and etiological mechanisms. J Autoimmun 2014; 52: 90-100. DOI: https://doi.org/10.1016/j.jaut.2013.12.011
Garcia-Carrasco M, Escarcega RO, Fuentes-Alexandro S, Riebeling C, Cervera R. Therapeutic options in autoimmune myasthenia gravis. Autoimmun Rev 2007; 6: 373-8. DOI: https://doi.org/10.1016/j.autrev.2007.01.001
Rodolico C, Nicocia G, Damato V, Antonini G, Liguori R, Evoli A. Benefit and danger from immunotherapy in myasthenia gravis. Neurol Sci 2021; 42: 1367-75. DOI: https://doi.org/10.1007/s10072-021-05077-6
Lee JS, Joo IS, Seok JI. Widely varying TNF-alpha levels in patients with myasthenia gravis Neurol Sci 2009; 30: 259-62. DOI: https://doi.org/10.1007/s10072-009-0023-0
Bruzzese V, Marrese C, Scolieri P, Hassan C, Lorenzetti R, Zullo A. Myasthenia gravis onset during rheumatic disease: a new paradoxical effect of anti-TNF alpha therapy? Int J Rheum Dis 2015; 18: 375-6. DOI: https://doi.org/10.1111/1756-185X.12340
Nicocia G, Bonanno C, Lupica A, Toscano A, Rodolico C. Myasthenia gravis after etanercept and ustekinumab treatment for psoriatic arthritis: a case report. Neuromuscul Disord 2020; 30: 246-9. DOI: https://doi.org/10.1016/j.nmd.2020.01.001
Pelechas E, Memi T, Markatseli TE, Voulgari PV, Drosos AA. Adalimumab-induced myasthenia gravis: case-based review. Rheumatol Int 2020; 40: 1891-4. DOI: https://doi.org/10.1007/s00296-020-04587-4
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
